Spero Therapeutics (SPRO) Net Income towards Common Stockholders (2016 - 2026)
Quarterly Net Income towards Common Stockholders rose 48.06% to -$7.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $15.2 million through Mar 2026, up 120.72% year-over-year, with the annual reading at $8.6 million for FY2025, 112.48% up from the prior year.
Spero Therapeutics filings provide 11 years of Net Income towards Common Stockholders readings, the most recent being -$7.2 million for Q1 2026.
- Net Income towards Common Stockholders hit -$7.2 million in Q1 2026 for Spero Therapeutics, down from $31.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $55.1 million in Q4 2023 and bottomed at -$30.1 million in Q1 2022.
- Average Net Income towards Common Stockholders over 5 years is -$5.0 million, with a median of -$11.9 million recorded in 2023.
- The largest annual shift saw Net Income towards Common Stockholders tumbled 454.02% in 2024 before it skyrocketed 230.92% in 2025.
- Spero Therapeutics' Net Income towards Common Stockholders stood at $27.5 million in 2022, then soared by 100.51% to $55.1 million in 2023, then tumbled by 143.68% to -$24.1 million in 2024, then skyrocketed by 230.92% to $31.5 million in 2025, then tumbled by 122.85% to -$7.2 million in 2026.
- Per Business Quant, the three most recent readings for SPRO's Net Income towards Common Stockholders are -$7.2 million (Q1 2026), $31.5 million (Q4 2025), and -$7.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.63 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Spero Therapeutics | 154.37 Mn | 98.24 Mn | - | -7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.20 Mn |
| Dec 31, 2025 | 31.52 Mn |
| Sep 30, 2025 | -7.38 Mn |
| Jun 30, 2025 | -1.70 Mn |
| Mar 31, 2025 | -13.87 Mn |
| Dec 31, 2024 | -24.08 Mn |
| Sep 30, 2024 | -17.70 Mn |
| Jun 30, 2024 | -17.86 Mn |
| Mar 31, 2024 | -12.66 Mn |
| Dec 31, 2023 | 55.11 Mn |
| Sep 30, 2023 | -3.20 Mn |
| Jun 30, 2023 | -11.91 Mn |
| Mar 31, 2023 | -13.26 Mn |
| Dec 31, 2022 | 27.49 Mn |
| Sep 30, 2022 | -11.47 Mn |
| Jun 30, 2022 | -25.97 Mn |
| Mar 31, 2022 | -30.14 Mn |
| Dec 31, 2021 | -27.43 Mn |
| Sep 30, 2021 | -22.43 Mn |
| Jun 30, 2021 | -18.46 Mn |
| Mar 31, 2021 | -19.31 Mn |
| Dec 31, 2020 | -18.75 Mn |
| Sep 30, 2020 | -18.99 Mn |
| Jun 30, 2020 | -18.39 Mn |
| Mar 31, 2020 | -22.58 Mn |
| Dec 31, 2019 | -25.56 Mn |
| Sep 30, 2019 | -17.58 Mn |
| Jun 30, 2019 | -13.29 Mn |
| Mar 31, 2019 | -5.46 Mn |
| Dec 31, 2018 | -10.60 Mn |
| Sep 30, 2018 | -10.46 Mn |
| Jun 30, 2018 | -9.96 Mn |
| Mar 31, 2018 | -10.64 Mn |
| Dec 31, 2017 | -14.77 Mn |
| Sep 30, 2017 | -12.08 Mn |
| Jun 30, 2017 | -12.12 Mn |
| Mar 31, 2017 | -7.13 Mn |
| Dec 31, 2016 | -8.33 Mn |
| Sep 30, 2016 | -7.41 Mn |